

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934

For the month of December 2021

Commission file number: 001-40753

**ICECURE MEDICAL LTD.**  
(Translation of registrant's name into English)

**7 Ha'Eshel St., PO Box 3163**  
**Caesarea, 3079504 Israel**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): \_\_\_\_\_

---

---

**CONTENTS**

On November 24, 2021, IceCure Medical Ltd. (the "Company" or "IceCure") submitted a pre-submission package to the U.S. Food and Drug Administration (the "FDA") in which the Company proposed an intended use for early stage breast cancer and high risk to surgery for the Company's IceCure family of systems and suggested a De Novo classification. Since the Company was previously granted Breakthrough Device Designation from the FDA for its ProSense system, this pre-submission package included a request for a sprint discussion under FDA procedures.

---

1

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**IceCure Medical Ltd.**

Date: December 3, 2021

By: /s/ Eyal Shamir  
Name: Eyal Shamir  
Title: Chief Executive Officer

---

2

---